Use of anti-cgrp antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated cgrp levels

A method of inhibiting, preventing or treating diarrhea in a subject comprising elevated levels of CGRP, wherein said elevated CGRP levels are associated with an acute condition comprising administering an effective amount of an anti-CGRP antibody or anti-CGRP antibody fragment, wherein the anti-CGRP antibody or antibody fragment is selected from the following:

• (i) one which comprises the variable light (VL) CDR1, CDR2, and CDR3 of SEQ ID NOs:5, 6 and 7, respectively, and the variable heavy (VH) CDR1, CDR2, and CDR3 of SEQ ID NOs:8, 9 and 10, respectively;
• (ii) one which comprises the variable light (VL) CDR1, CDR2, and CDR3 of SEQ ID NOs:15, 16 and 17, respectively, and the variable heavy (VH) CDR1, CDR2, and CDR3 of SEQ ID NOs:18, 19 and 20, respectively;
• (iii) one which comprises the variable light (VL) CDR1, CDR2, and CDR3 of SEQ ID NOs:25, 26 and 27, respectively, and the variable heavy (VH) CDR1, CDR2, and CDR3 of SEQ ID NOs:28, 29 and 30, respectively;
• (iv) one which comprises the variable light (VL) CDR1, CDR2, and CDR3 of SEQ ID NOs:35, 36 and 37, respectively, and the variable heavy (VH) CDR1, CDR2, and CDR3 of SEQ ID NOs:38, 39 and 40, respectively;
• (v) one which comprises the variable light (VL) CDR1, CDR2, and CDR3 of SEQ ID NOs:45, 46 and 47, respectively, and the variable heavy (VH) CDR1, CDR2, and CDR3 of SEQ ID NOs:48, 49 and 50, respectively;
• (vi) one which comprises the variable light (VL) CDR1, CDR2, and CDR3 of SEQ ID NOs:55, 56 and 57, respectively, and the variable heavy (VH) CDR1, CDR2, and CDR3 of SEQ ID NOs:58, 59 and 60, respectively;
• (vii) one which comprises the variable light (VL) CDR1, CDR2, and CDR3 of SEQ ID NOs:65, 66 and 67, respectively, and the variable heavy (VH) CDR1, CDR2, and CDR3 of SEQ ID NOs:68, 69 and 70, respectively;
• (viii) one which comprises the variable light (VL) CDR1, CDR2, and CDR3 of SEQ ID NOs:75, 76 and 77, respectively, and the variable heavy (VH) CDR1, CDR2, and CDR3 of SEQ ID NOs:78, 79 and 80, respectively;
• (ix) one which comprises the variable light (VL) CDR1, CDR2, and CDR3 of SEQ ID NOs:85, 86 and 87, respectively, and the variable heavy (VH) CDR1, CDR2, and CDR3 of SEQ ID NOs:88, 89 and 90, respectively;
• (x) one which comprises the variable light (VL) CDR1, CDR2, and CDR3 of SEQ ID NOs:95, 96 and 97, respectively, and the variable heavy (VH) CDR1, CDR2, and CDR3 of SEQ ID NOs:98, 99 and 100, respectively;
• (xi) one which comprises the variable light (VL) CDR1, CDR2, and CDR3 of SEQ ID NOs:105, 106 and 107, respectively, and the variable heavy (VH) CDR1, CDR2, and CDR3 of SEQ ID NOs:108, 109 and 110, respectively;
• (xii) one which comprises the variable light (VL) CDR1, CDR2, and CDR3 of SEQ ID NOs:115, 116 and 117, respectively, and the variable heavy (VH) CDR1, CDR2, and CDR3 of SEQ ID NOs:118, 119 and 120, respectively;
• (xiii) one which comprises the variable light (VL) CDR1, CDR2, and CDR3 of SEQ ID NOs:125, 126 and 127, respectively, and the variable heavy (VH) CDR1, CDR2, and CDR3 of SEQ ID NOs:128, 129 and 130, respectively;
• and
• (xiv) one which comprises the variable light (VL) CDR1, CDR2, and CDR3 of SEQ ID NOs:135, 136 and 137, respectively, and the variable heavy (VH) CDR1, CDR2, and CDR3 of SEQ ID NOs:138, 139 and 140, respectively.